Clene (NASDAQ: CLNN) , together with its subsidiary Clene Nanomedicine Inc., is preparing to initiate neurofilament biomarker analyses for its lead d ...

Somewhere between recycled meme coins and overhyped layer-2s projects, a new batch of projects is quietly stealing the ...

In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain amyloidosis ...

In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

As the dynamic world of cryptocurrencies continues to evolve and mature, savvy investors are looking for the moonshot potential to capitalise on high ROI in ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

Crypto presales are heating up, with Lightchain AI and BlockDAG drawing serious attention from market watchers. Lightchain AI ...

Along with the fact that cryptocurrency is gaining momentum, crypto with 100x potential becomes increasingly appealing to early investors and adopters seeking the next big cryptocurrency projects.

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming ...

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

We read with great interest the Article by Randall J Bateman and colleagues investigating long-term gantenerumab treatment in dominantly inherited Alzheimer's disease.1 This important work provides ...